Isracann Enters MOU for European Distribution

Ryan Allway

January 2nd, 2020

App, News, Top News

Access is key to building brand recognition and added value

VANCOUVER, BC, — (GLOBE NEWSWIRE – January 2, 2020) – Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) an Israel-based business focused on becoming a premier low cost, high quality cannabis producer for both domestic and European export sales is pleased to announce entry into a Memorandum of Understanding (“MOU”) towards a distribution agreement serving key legalized European cannabis markets.

Due to commercial practicalities, the currently unnamed distributor has provisionally agreed to enter an understanding with Isracann towards a strategic export and processing opportunity as part of a pending definitive agreement. The agreement in principal proposes a non-binding option on dried flower product subject to Israeli export laws and defined by minimum quantity, quality and period of delivery.

The proposed distributor represents that they will import the product through the Republic of Malta, subject to compliance with jurisdictional importation and transhipment regulations. The distributor asserts its plan to utilize the Isracann product as raw input for value added processing, extraction, packaging, branding and export distribution.

As part of the agreement, the distributor further asserts it is preparing a regional processing facility designed to meet European Union Good Manufacturing Practice (EU-GMP) as stipulated by the EU as a regulatory requirement for medicinal products.

Mr. Darryl Jones, Isracann’s CEO states, “Well before we began our agricultural efforts in Israel, we recognized the need for strategic distribution agreements. Malta has long been on our radar due to its favourable business environment, excellent logistics and proximity to major European markets. While we continue to build momentum in Israel, we concurrently undertook to identify a potential partner with a similar big picture vision and goals. We believe this agreement can expedite our entry into these markets as purveyors of what we aim to brand as the gold standard of Israel’s cannabis export sector.”

Isracann has previously announced that Germany is its stated target for entry into the EU markets pending achievement of Israeli export licensing approval. Germany legalized medical cannabis in March 2017 and today is the largest medical cannabis market in Europe. With a potential patient base of over 1 million patients, it stands to grow substantially over the next several years.

“The team here at Isracann believes that beyond Germany, future markets such as Denmark and the United Kingdom are poised to help grow the entire region into an immense opportunity much larger and more sophisticated than currently found in the Americas,” continues Mr. Jones. “Our announcement today is part of our fundamental strategy and marks the beginning of the next chapter in our development. We are excited to begin the decade with new alliances and opportunities ahead.”

ON BEHALF OF THE BOARD OF DIRECTORS

“Darryl Jones”
Darryl Jones
Chief Executive Officer and President

About Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF)

Isracann is an Israeli-based cannabis company focused on becoming a premier cannabis producer offering low-cost production targeting undersupplied, major European marketplaces. Based in Israel’s agricultural sector, Isracann will leverage its development within the most experienced country in the world with respect to cannabis research. The Company has secured agreements within Israel for medicinal marijuana cultivation. For more information visit: www.isracann.com.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

All statements, other than statements of historical fact, included herein are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ, materially from the Company’s expectations are disclosed in the Company’s documents filed from time to time with the Canadian Securities Exchange, the British Columbia Securities Commission, the Ontario Securities Commission, and the Alberta Securities Commission.

Isracann BioSciences
inquiries@isracann.com
(855) 205-0226
www.isracann.com

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Search CannabisFN

Press Coverage

Psychedelics Index

Visit the CFN Video Library

Join Our Facebook Page

Top Videos

Rob Sechrist of Pelorus Equity Group

Rob is the co-founding President of Pelorus Equity Group and has more than 18 years of experience in the real estate finance industry. Since the formation of Pelorus in 2010, he has raised more than $175,000,000 in secured real estate transactions. Rob’s primary role at Pelorus Equity Group is the development of strategic alliances with […]

CFN Media / Paul Rosen

Watch CFN Media’s exclusive three part interview with Paul Rosen, one of the most active and diversified investors in the emerging cannabis industry. Paul gives his insights on the global cannabis industry and discusses his new endeavors. Become a CFN Media Client Paul Rosen is a noted career entrepreneur and management consultant. Over the last […]

Geyser Brands Inc.

Geyser Brands Inc builds health-based hemp CBD consumer products in the Nutraceutical, Cosmetics, Food & Beverage and Pet sectors world-wide.

Zenabis Global Inc.

Zenabis owns 660,000 square feet of high quality indoor facility space, as well as 2.1 million square feet of greenhouse space that will be dedicated to cannabis production once fully built-out.

Network Partners

Follow Us on Social Media

Facebook

Twitter

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.